Posts by: Patricia Inacio PhD

News

Immunocore presented data showing that its leading investigational immunotherapy, IMCgp100, leads to durable tumor responses and strong survival rates in patients with advanced uveal melanoma, following two Phase 1 clinical trials. ... Read more

November 8, 2017

FDA OKs Batu Biologics’ ValloVax for Clinical Investigation in Certain Solid Tumors

News

The U.S. Food and Drug Administration (FDA) has cleared Batu Biologics to advance its immunotherapy, ValloVax, into clinical trials for certain solid tumors, the company announced. This is the first immunotherapy targeting the blood ... Read more

November 2, 2017

Opdivo Moves a Step Closer to Being Expanded to Another Melanoma Patient Population

News

Regulators have taken a step toward expanding the European Union’s approval of Opvido (nivolumab) as a melanoma treatment to an additional group of patients. The step the European Medicines Agency took was accepting Bristol-Myers ... Read more

October 4, 2017October 4, 2017

First Clinical Trial Testing NBTXR3 Plus Immune Checkpoint Inhibitors to Recruit Patients in the US

News

The late-clinical-stage company Nanobiotix, which works toward developing new cancer treatment approaches, announced that it will soon launch its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors ... Read more

September 12, 2017September 12, 2017

Keytruda Continues to Show Promise in Advanced Stomach Cancer Patients, Updated KEYNOTE-059 Data Show

News

Keytruda (pembrolizumab) is safe and has shown promising anti-tumor activity in patients with advanced gastric or gastroesophageal junction (GEJ) cancer, according to data presented at the European Society for Medical Oncology (ESMO) ... Read more

September 6, 2017September 6, 2017

Keytruda Approved in Europe for Certain Bladder Cancer Patients

News

The European Commission (EC) has approved Keytruda (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, according to the therapy’s maker, Merck, known as MSD outside the United ... Read more

August 25, 2017

Argos to Present Interim Results of Phase 3 ADAPT Trial for Renal Cell Cancer

News

Interim results from the ongoing Phase 3 ADAPT clinical trial for the investigational therapy Rocapuldencel-T (AGS-003) in patients with metastatic renal cell carcinoma, will be presented at the 2017 Congress ... Read more

August 4, 2017

FDA Approves Opdivo for Two Metastatic Colorectal Cancers That Failed to Respond to Chemo

News

The U.S. Food and Drug Administration has approved the immunotherapy Opdivo (nivolumab) as a treatment for two colorectal cancers that failed to respond to a chemotherapy combination, according to its developer, Bristol-Myers Squibb. Opdivo becomes ... Read more

August 3, 2017

FDA Grants Breakthrough Therapy Status to Imfinzi for Unresectable NSCLC

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Imfinzi (durvalumab) for patients with locally advanced, unresectable (unable to be removed with surgery) non-small cell lung cancer (NSCLC), ... Read more

June 23, 2017July 4, 2017

Ilixadencel Provokes Strong Response Against Kidney Cancer, Phase 1/2 Clinical Trial Shows

News

Injecting ilixadencel into the tumors of newly diagnosed metastatic kidney cancer patients provoked a potent immune response to the disease, according to the first stage of a Phase 1/2 clinical ... Read more